The company expired its plan on April 3, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.12 CNY | +0.20% | +2.79% | -35.69% |
04-26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
04-25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.69% | 3.34B | |
-3.66% | 89.33B | |
+4.08% | 41.19B | |
-15.09% | 31.87B | |
+53.68% | 24.52B | |
-15.13% | 15.68B | |
-8.63% | 12.34B | |
-40.39% | 12.23B | |
+6.22% | 8.83B | |
-6.32% | 8.28B |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Walvax Biotechnology Co., Ltd.'s Equity Buyback announced on April 5, 2023, has expired with 2,000,000 shares, representing 0.12% for CNY 72.2 million.